戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  well as the only case that was treated with botulinum toxin A.
2 ridgewater, NJ) and periocular injections of botulinum toxin A.
3 or when vesicular release was inhibited with botulinum toxin A.
4 roposal as third line for strong opioids and botulinum toxin A.
5  adverse events associated with injection of botulinum toxin A.
6  light chain, the metalloprotease domain, of botulinum toxin A.
7 fficacy and safety of one-time injections of botulinum toxin A (200 to 240 units) in 126 subjects wit
8 nts were randomized to receive intralesional botulinum toxin A (5 U per 1 cm2) or equivalent volumes
9 ivator forskolin is blocked completely after Botulinum toxin A action.
10 ghly concentrated, unlicensed preparation of botulinum toxin A and may have received doses 2857 times
11 as no significant association between use of botulinum toxin A and reduction in the number of episodi
12  enterotoxins A and B, cholera toxin, ricin, botulinum toxin A, and heat labile toxin of E. coli).
13 staphylococcal enterotoxin A, cholera toxin, botulinum toxin A, and ricin in model buffer (PBS-BSA) a
14 ococcal enterotoxins A and B, cholera toxin, botulinum toxin A, and ricin increased 2- to 5-fold, whi
15 tidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for lidocaine patche
16                           Topical agents and botulinum toxin A are recommended for peripheral neuropa
17                                              Botulinum toxin A (Botox) is commonly used for strabismu
18                                              Botulinum toxin A (BT) is used therapeutically for the t
19 ical trial to compare topical diltiazem with botulinum toxin A (BTA) in the treatment of chronic anal
20                         We hypothesized that botulinum toxin A (BTA) would prolong analgesia after sy
21 bjects were pretreated, subcutaneously, with botulinum toxin A (BTX-A) to inhibit the release of neur
22                    A unilateral injection of botulinum toxin A (BTxA) in the calf induces paralysis a
23  demonstrate that clinical use of unlicensed botulinum toxin A can result in severe, life-threatening
24                                              Botulinum toxin A compared with placebo was associated w
25 ion of the light chains of tetanus toxin and botulinum toxin A did not disrupt the restricted motion
26 oteins play a role in short-term plasticity, Botulinum toxins A, E, and F, were used to disrupt SNARE
27                        Subjects who received botulinum toxin A had greater improvement in flexor tone
28                        Subjects treated with botulinum toxin A had greater improvement in the princip
29                                              Botulinum toxin A-induced muscle paralysis caused pronou
30                                   Subsequent botulinum toxin A injections allowed spontaneous eyelid
31 d limb use by the intramuscular injection of botulinum toxin A into selected forelimb muscles to prod
32 oaded pocketed microneedle device to deliver botulinum toxin A into the human dermis with the aim of
33 ar chemodenervation agents (alcohol, phenol, botulinum toxin A), intrathecally administered drugs (ba
34                                     Although botulinum toxin A is available by prescription for cosme
35                                              Botulinum toxin A is the most commonly used treatment fo
36                                              Botulinum toxin A is US Food and Drug Administration app
37 by treating organotypic cultures of SCN with botulinum toxin A or dynasore to block exocytosis and en
38                  Intramuscular injections of botulinum toxin A reduce spasticity of the wrist and fin
39 shown that proteolytic cleavage of SNAP25 by botulinum toxin A reduces the ability of Gbetagamma to c
40                Intrasphincteric injection of botulinum toxin A represents a novel technique to treat
41 rmed at P7 for WT, cKO, and muscle-unloaded (botulinum toxin A treated) attachments for quantitative
42                       Compared with placebo, botulinum toxin A was associated with a greater frequenc
43                                              Botulinum toxin A was associated with fewer chronic tens
44               Pooled analyses suggested that botulinum toxin A was associated with fewer headaches pe
45                            In single trials, botulinum toxin A was not associated with fewer migraine
46       Randomized controlled trials comparing botulinum toxin A with placebo or other interventions fo

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。